Source: https://patents.justia.com/patent/8512394
Timestamp: 2020-03-29 03:26:10
Document Index: 486285315

Matched Legal Cases: ['art\n6585760', 'arty\n6602497', 'Application No. 2005269686', 'Application No. 200580024291', 'Application No. 200580024291', 'Application No. 05779404', 'Application No. 2007', 'Application No. 2007105205', 'Application No. 2573886', 'Application No. 05779404', 'Application No. 2007']

US Patent for Balloon expandable crush-recoverable stent device Patent (Patent # 8,512,394 issued August 20, 2013) - Justia Patents Search
Justia Patents Stent StructureUS Patent for Balloon expandable crush-recoverable stent device Patent (Patent # 8,512,394)
Jul 26, 2010 - Reva Medical Inc.
Latest Reva Medical Inc. Patents:
Devices, compositions and methods for bone and tissue augmentation
This application is a continuation of U.S. application Ser. No. 10/897,235, filed Jul. 21, 2004, the entirety of which is hereby incorporated herein by reference.
Balloon expandable stents are manufactured in the collapsed condition and are expanded to a desired diameter with a balloon. During delivery, a balloon expandable stent is typically mounted on the exterior of an inflatable balloon located along the distal end portion of a catheter. After reaching the treatment site, the stent is expanded from the collapsed condition to the expanded condition by inflating the balloon. The stent is typically expanded to a diameter that is greater than or equal to the inner diameter of the body lumen. The expandable stent structure may be held in the expanded condition by mechanical deformation of the stent as taught in, for example, U.S. Pat. No. 4,733,665 to Palmaz. Alternatively, balloon expandable stents may be held in the expanded condition by engagement of the stent walls with respect to one another as disclosed in, for example, U.S. Pat. Nos. 4,740,207 to Kreamer, 4,877,030 to Beck et al., and 5,007,926 to Derbyshire. Further still, the stent may be held in the expanded condition by one-way engagement of the stent walls together with endothelial growth into the stent, as disclosed in U.S. Pat. No. 5,059,211 to Stack et al.
1. A balloon-expandable crush-recoverable stent, comprising:
a tubular member having a longitudinal axis and a circumferential axis, the tubular member comprising first and second expandable modules linked by at least one flexible member, the at least one flexible member configured to allow the first expandable module to expand to a first expanded diameter and the second expandable module to expand to a second expanded diameter, wherein the first and second expandable modules can be independently actuated and wherein the first and second expanded diameters are independently selectable;
wherein the first expandable module includes a first plurality of substantially non-deforming radial elements slidably-connected to allow the first expandable module to expand from a collapsed diameter to the first expanded diameter in response to an expansive force, a first locking mechanism for maintaining the first expandable module in the expanded diameter after deployment at a treatment site, and a first constraining mechanism for maintaining the first expandable module in the collapsed diameter until released during deployment at a treatment site;
wherein the second expandable module includes a second plurality of substantially non-deforming radial elements slidably-connected to allow the second expandable module to expand from a collapsed diameter to the second expanded diameter in response to an expansive force, a second locking mechanism for maintaining the second expandable module in the expanded diameter after deployment at a treatment site, and a second constraining mechanism for maintaining the second expandable module in the collapsed diameter until released during deployment at a treatment site; and
wherein neither the first constraining mechanism nor the second constraining mechanism pass through a closed passage extending circumferentially between a first opening and a second opening, the first and second openings being substantially perpendicular to the circumferential axis.
2. The stent of claim 1, wherein the first and second modules are substantially identical.
3. The stent of claim 1, wherein at least one of the substantially non-deforming radial elements is fabricated from a shape-memory material for providing crush-recoverability.
4. The stent of claim 1, wherein the first and second constraining mechanisms are configured to be released by radial expansion of an inflatable balloon during deployment at a treatment site.
5. The stent of claim 1, wherein diameter of the deployed stent varies along the longitudinal axis.
6. The stent of claim 1, wherein the first and second locking mechanisms each comprise an engagement member configured to engage one or more teeth disposed on the respective ones of the first and second pluralities of substantially non-deforming radial elements for allowing slidable movement in substantially only one direction.
7. The stent of claim 6, wherein the teeth are deflectable for allowing the engagement members to pass over the teeth during expansion of the respective first and second expandable modules.
8. The stent of claim 1, wherein the first and second expandable modules are configured such that the first and second constraining mechanisms each further comprise a hook disposed along at least one of the radial elements, the hook being configured to be releasably held within a loop-shaped member on an adjacent radial element during delivery to the treatment site.
9. The stent of claim 1, further comprising a retractable sheath sized for enclosing the tubular member during delivery to a treatment site.
10. The stent of claim 1, wherein the radial elements are substantially identical to one another.
11. A balloon-expandable crush-recoverable stent, comprising:
a tubular member comprising: at least one flexible linkage element connecting at least two expandable modules along a longitudinal axis of the tubular member, wherein each expandable module comprises first and second inner rails and first and second outer rails and a circumferential centerline, each of the first and second inner rails and the first and second outer rails extending from an end portion of the module to a circumferentially opposite end portion of the module, the first outer rail being positioned outwardly of the first inner rail relative to the circumferential centerline, the second outer rail being positioned outwardly of the second inner rail relative to the circumferential centerline, and wherein each module is configured to radially expand independently of the other module thereby allowing the tubular member to be expanded to various diameters along the longitudinal axis of the tubular member; a locking mechanism provided along the tubular member for maintaining the tubular member in the expanded diameter after deployment at a treatment site; and a constraining mechanism located on at least one of the outer rails for maintaining the tubular member in the collapsed diameter until released by radial expansion of an inflatable balloon during deployment at a treatment site.
12. The stent of claim 11, wherein the locking mechanism comprises a plurality of teeth along a first end portion and an engagement member along a second end portion and wherein the engagement member is configured for slidable engagement with the teeth.
13. The stent of claim 11, wherein the constraining mechanism comprises a hold-down tab along a first end portion and a recess along a second end portion, wherein the recess is configured for capturing the hold-down tab.
14. The stent of claim 11, wherein the tubular member is configured to deliver a therapeutic agent to a vessel wall at a treatment site.
15. The stent of claim 11, wherein the tubular member is formed from one or more substantially flat sheets fabricated from a shape-memory material, the one or more flat sheets being configured to be rolled into a cylindrical configuration to form the tubular member.
16. The stent of claim 11, wherein the inner and outer sets of rails are substantially parallel to a circumferential centerline of the module.
17. The stent of claim 11, wherein the first and second inner rails are not connected to each other or the outer rails throughout the length of the rails.
18. The stent of claim 11, wherein the constraining mechanism is configured to flex outwards relative to the circumferential centerline.
19. The stent of claim 18, wherein the constraining mechanism comprises a tab and a plurality of circumferentially spaced recesses, the tab being configured to engage at least one of the recesses during radial expansion of the tubular member.
20. The stent of claim 19, wherein the constraining mechanism is configured to flex outwards during engagement of the tab and the at least one of the recesses.
2361506 October 1944 Gray et al.
4383555 May 17, 1983 Finley
4576532 March 18, 1986 Hanson et al.
4714508 December 22, 1987 Chivens et al.
4788751 December 6, 1988 Shely et al.
5242997 September 7, 1993 Kohn et al.
5264537 November 23, 1993 Kohn et al.
5317077 May 31, 1994 Kohn et al.
5402554 April 4, 1995 Oetiker
5423321 June 13, 1995 Fontenot
5496275 March 5, 1996 Sirhan et al.
5545135 August 13, 1996 Iacob et al.
5800393 September 1, 1998 Sahota
5868747 February 9, 1999 Ochoa et al.
5944726 August 31, 1999 Blaeser et al.
6048521 April 11, 2000 Kohn et al.
6093157 July 25, 2000 Chandrasekaran
6132457 October 17, 2000 Chobotov
6156062 December 5, 2000 McGuiness
6183503 February 6, 2001 Hart et al.
6190403 February 20, 2001 Fishchell et al.
6197789 March 6, 2001 Grainger
6264624 July 24, 2001 Desmond, III et al.
6309350 October 30, 2001 Van Tassel et al.
6319492 November 20, 2001 Kohn et al.
6425915 July 30, 2002 Khosravi et al.
6447508 September 10, 2002 Sharkey et al.
6491704 December 10, 2002 Gifford, III et al.
6497671 December 24, 2002 Ferrera et al.
6562021 May 13, 2003 Derbin et al.
6569441 May 27, 2003 Kunz et al.
6582472 June 24, 2003 Hart
6585760 July 1, 2003 Fogarty
6602497 August 5, 2003 Kohn et al.
6610086 August 26, 2003 Kock et al.
6620356 September 16, 2003 Wong et al.
6623491 September 23, 2003 Thompson
6645143 November 11, 2003 Van Tassel et al.
6652555 November 25, 2003 Van Tassel et al.
6676658 January 13, 2004 Burbank et al.
6702846 March 9, 2004 Mikus et al.
6709449 March 23, 2004 Camrud et al.
6736838 May 18, 2004 Richter
6736844 May 18, 2004 Glatt et al.
6746477 June 8, 2004 Moore
6802849 October 12, 2004 Blaeser et al.
6852308 February 8, 2005 Kohn et al.
6869143 March 22, 2005 Secord
6878159 April 12, 2005 Iwasaka et al.
6916868 July 12, 2005 Kemnitzer et al.
6962604 November 8, 2005 Hijlkema
6964680 November 15, 2005 Shanley
6991647 January 31, 2006 Jadhav
7041126 May 9, 2006 Shin et al.
7056493 June 6, 2006 Kohn et al.
7077860 July 18, 2006 Yan et al.
7229473 June 12, 2007 Falotico et al.
7255710 August 14, 2007 White et al.
7279664 October 9, 2007 Weber
7476232 January 13, 2009 Deal
7520893 April 21, 2009 Rivelli
7553377 June 30, 2009 Chen et al.
7556644 July 7, 2009 Burpee et al.
7637939 December 29, 2009 Tischler
7704275 April 27, 2010 Schmid et al.
7763067 July 27, 2010 Bales et al.
7766960 August 3, 2010 Alexander et al.
7780721 August 24, 2010 Bales et al.
7812290 October 12, 2010 Weber
7846198 December 7, 2010 Hogendijk
7947071 May 24, 2011 Schmid
7988721 August 2, 2011 Morris et al.
20010010015 July 26, 2001 Hijlkema
20010020173 September 6, 2001 Klumb et al.
20010029378 October 11, 2001 Blaeser et al.
20010044651 November 22, 2001 Steinke et al.
20020010504 January 24, 2002 Alt et al.
20020040238 April 4, 2002 Rudnick et al.
20020052641 May 2, 2002 Monroe et al.
20020072656 June 13, 2002 Van Tassel et al.
20020193870 December 19, 2002 Jang
20030045923 March 6, 2003 Bashiri
20030069633 April 10, 2003 Richter et al.
20030074043 April 17, 2003 Thompson
20030176914 September 18, 2003 Rabkin et al.
20030199969 October 23, 2003 Steinke et al.
20030208262 November 6, 2003 Gaber
20030212451 November 13, 2003 Cox et al.
20030220682 November 27, 2003 Kujawski
20040062788 April 1, 2004 Richter
20040068316 April 8, 2004 Schaeffer
20040086458 May 6, 2004 Kohn et al.
20040086462 May 6, 2004 Kohn et al.
20040093076 May 13, 2004 White et al.
20040097959 May 20, 2004 Thompson
20040106971 June 3, 2004 Schwartz et al.
20040106977 June 3, 2004 Sullivan et al.
20040133260 July 8, 2004 Schwartz et al.
20040143319 July 22, 2004 Schwartz et al.
20040167616 August 26, 2004 Camrud et al.
20040186556 September 23, 2004 Hogendijk et al.
20040186557 September 23, 2004 Gambale et al.
20040191175 September 30, 2004 Kohn et al.
20040193251 September 30, 2004 Rudnick et al.
20040236401 November 25, 2004 Shin et al.
20040243218 December 2, 2004 Schaeffer
20050038503 February 17, 2005 Greenhalgh et al.
20050123481 June 9, 2005 Kohn et al.
20050165203 July 28, 2005 Kohn et al.
20050216076 September 29, 2005 Kveen et al.
20050246010 November 3, 2005 Alexander et al.
20060024266 February 2, 2006 Brandom et al.
20060026815 February 9, 2006 Padilla et al.
20060034769 February 16, 2006 Kohn et al.
20060036316 February 16, 2006 Zeltinger et al.
20060079955 April 13, 2006 Brown
20060115449 June 1, 2006 Pacetti
20060182779 August 17, 2006 Brandom et al.
20060204440 September 14, 2006 Kohn et al.
20070010870 January 11, 2007 Alt et al.
20070032854 February 8, 2007 Schmid et al.
20070032857 February 8, 2007 Schmid et al.
20070061004 March 15, 2007 Steinke
20070142901 June 21, 2007 Steinke
20070250148 October 25, 2007 Perry et al.
20070270939 November 22, 2007 Hood et al.
20080046066 February 21, 2008 Jenson et al.
20080051868 February 28, 2008 Cottone et al.
20080051873 February 28, 2008 Cottone et al.
20080051874 February 28, 2008 Cottone et al.
20080051875 February 28, 2008 Cottone et al.
20080071355 March 20, 2008 Weber
20080114391 May 15, 2008 Dieck et al.
20080183275 July 31, 2008 Schmid et al.
20080195190 August 14, 2008 Bland et al.
20080221664 September 11, 2008 Bales et al.
20080262599 October 23, 2008 Caro et al.
20080269869 October 30, 2008 Cho
20080288050 November 20, 2008 Addonizio et al.
20090030501 January 29, 2009 Morris et al.
20090143853 June 4, 2009 Morris et al.
20090187239 July 23, 2009 Goto
20100004725 January 7, 2010 Zipse et al.
20100042203 February 18, 2010 Cottone et al.
20100131048 May 27, 2010 Schmid et al.
20100256735 October 7, 2010 Morales
20100280593 November 4, 2010 Richter
20100286759 November 11, 2010 Taylor et al.
20100324662 December 23, 2010 Addonizio et al.
20110172759 July 14, 2011 Schmid et al.
20110245909 October 6, 2011 Schmid et al.
20110251674 October 13, 2011 Schmid et al.
20110282434 November 17, 2011 Morris et al.
07-000531 January 1995 JP
08-196641 August 1996 JP
08-336598 December 1996 JP
9-313617 December 1997 JP
WO 90/14046 November 1990 WO
WO 94/21196 February 1995 WO
WO 96/14030 May 1996 WO
WO 97/07751 March 1997 WO
WO 97/42911 November 1997 WO
WO 98/22073 May 1998 WO
WO 98/41169 September 1998 WO
WO 98/22073 February 1999 WO
WO 99/08740 February 1999 WO
WO 99/15106 April 1999 WO
WO 99/40874 August 1999 WO
WO 99/65421 January 2000 WO
WO 00/09195 February 2000 WO
WO 00/30565 June 2000 WO
WO 00/59405 October 2000 WO
WO 00/71058 November 2000 WO
WO 01/24735 April 2001 WO
WO 01/51114 July 2001 WO
WO 01/70298 September 2001 WO
WO 01/87180 November 2001 WO
WO 01/51114 January 2002 WO
WO 01/70298 February 2002 WO
WO 00/62708 June 2002 WO
WO 01/87180 June 2002 WO
WO 02/47582 June 2002 WO
WO 02/053204 July 2002 WO
WO 02/054990 July 2002 WO
WO 02/047582 October 2002 WO
WO 02/054990 November 2002 WO
WO 02/053204 March 2003 WO
WO 03/047464 June 2003 WO
WO 03/057076 July 2003 WO
WO 03/047464 September 2003 WO
WO 03/047464 November 2003 WO
WO 03/094798 November 2003 WO
WO 03/099161 February 2004 WO
WO 2004/019820 March 2004 WO
WO 2004/026112 April 2004 WO
WO 2004/032803 April 2004 WO
WO 2004/026112 June 2004 WO
WO 2004/026112 October 2004 WO
WO 2004/087015 October 2004 WO
WO 2004/096340 November 2004 WO
WO 2004/110312 December 2004 WO
WO 2006/010636 February 2006 WO
WO 2006/014596 February 2006 WO
WO 2006/020616 February 2006 WO
WO 2006/107608 October 2006 WO
WO 2007/084444 July 2007 WO
WO 2010/022005 February 2010 WO
WO 2010/042879 April 2010 WO
WO 2011/127452 October 2011 WO
Office Action received in corresponding Austrialian Application No. 2005269686, mailed May 19, 2008, 3 pages.
Office Action received in corresponding Chinese Application No. 200580024291.7, mailed Jul. 24, 2009.
Office Action received in corresponding Chinese Application No. 200580024291.7, mailed Jun. 29, 2010.
Office Action received in corresponding European Application No. 05779404.2, mailed Feb. 26, 2010.
Office Action received in corresponding Japanese Application No. 2007-522683, mailed Nov. 5, 2010.
Office Action received in corresponding Russian Application No. 2007105205, mailed Jun. 24, 2009.
International Search Report and Written Opinion, mailed Sep. 11, 2005 in related International Application No. PCT/2005/025683, 13 pages.
Asahara, T. “Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-insured rate carotid artery,” Circulation 91: 2793-2801, 1995.
Autieri, M.V. et al. “Antisense oligonucleotides to the p65 subunit of NF-Kb inhibit human vascualr smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries,” Biochemical and Biophysical Research Communications 213: 827-836, 1995.
Brauner, R. “Controlled periadverntitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts,” The Journal of Thoracic and Cardiovascular Surgery 114: 53-63, 1997.
Carmeliet, P. et al. “Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation,” Circulation 96: 3180-3191, 1997.
Epstein, S.E. et al. “Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells,” Circulation 84: 778-787, 1991.
Hu, Y. “Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin,” Circulation 100: 861-868, 1999.
Kurisu, Y. et al. “Protective effect of beraprost sodium, a stable prostacyclin analogue, on cardiac allograft vasculopathy in rats,” Hiroshima Journal of Medical Science 56: 11-19, 1997.
Morishita, R. et al. “Novel in vitro gene transfer method for study of local modulators in vascular smooth muscle cells,” Hypertension 21: 894-899, 1993.
Nerem, R.M. et al. “Tissue engineering and the vascular system, synthetic biodegradable polymer scaffolds,” pp. 164-185, 1997.
Von Der Leyen, H.E. et al. “Gene therapy neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene,” PNAS USA 92:1137-1141, 1995.
Yasukawa, H. “Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte funtion, Associated antigen-1,” Circulation 95: 1515-1522, 1997.
Balcon, R. et al., Recommendations on stent manufacture, implantation and utilization, European Heart Journal, Oct. 1997, vol. 18, pp. 1536-1547.
Charles, Roger et al., Ceramide-Coated Balloon Catheters Limit Neointimal Hyperplasia After Stretch Injury in Carotid Arteries, Circulation Research, 2000; 87; pp. 282-288.
Coroneos, Emmanuel et al., Differential Regulation of Sphingomyelinase and Ceramidase Activities by Growth Factors and Cytokines, The Journal of Biological Chemistry, Oct. 6, 1995, vol. 270, No. 40, pp. 23305-23309.
Coroneos, Emmanuel et al., Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades, Biochem. J., 1996, 316, pp. 13-17 (Printed in Great Britain).
Jacobs, Leila S. et al., Sphingolipids as mediators of effects of platelet-derived growth factor in vascular smooth muscle cells, Am J Physiol (American Physiological Society), 1993, pp. C740-C747.
Tanguay, Jean Francois et al., Current Status of Biodegradable Stents, Cardiology Clinics, Contemporary Interventional Techniques, Nov. 1994, vol. 12, No. 4, pp. 699-713, W.B. Saunders Company.
Nikol, S. et al., Molecular biology and post-angioplasty restenosis, Atherosclerosis, 1996; 123, pp. 17-31.
Phillips, Paul S. MD, et al., The Stenter's Notebook, 1998, (entire book), Physicians' Press, Birmingham, Michigan.
Ratner, Buddy D. et al., Biomaterials Science, An Introduction to Materials in Medicine, 2nd Edition, 2004, (entire book), Elsevier Academic Press.
Serruys, Patrick W. et al., Handbook of Coronary Stents, Fourth Edition, 2002, (entire book), Martin Dunitz Ltd.
Atala, Anthony et al., Synthetic Biodegradable Polymer Scaffolds, 1997, (entire book), Birkhauser Boston.
Co-pending U.S. Appl. No. 60/866,281, filed Nov. 17, 2006. Title: Halogen-Containing Aromatic Polyesters and Polyamides for Medical Applications.
Co-pending U.S. Appl. No. 60/885,600, filed Jan. 18, 2007. Title: Halogen-Containing Aromatic Polyesters and Polyamides for Medical Applications.
Co-pending U.S. Appl. No. 60/852,471, filed Oct. 17, 2006. Title: N-Substituted Monomers and Polymers.
Co-pending U.S. Appl. No. 60/852,513, filed Oct. 17, 2006. Title: N-Substituted Monomers and Polymers.
International Preliminary Report on Patentability, mailed Jan. 23, 2007 in related International Application No. PCT/2005/025683, 9 pages.
Office Action received in corresponding Canadian Application No. 2573886, mailed Feb. 13, 2012, 3 pages.
Office Action received in corresponding European Application No. 05779404.2, mailed May 3, 2012.
Office Action received in corresponding Japanese Application No. 2007-522683, mailed Oct. 5, 2011.
Patent number: 8512394
Patent Publication Number: 20100292773
Assignee: Reva Medical Inc. (San Diego, CA)
Inventors: Eric V. Schmid (San Diego, CA), Andrew Morris (San Diego, CA), John Nguyen (San Diego, CA), Robert F. Eisele (Carlsbad, CA), Steven C. Howard (San Diego, CA), Orlando M. Padilla (Laguna Niguel, CA), Philip J. Simpson (Escondido, CA)
Application Number: 12/843,838